Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 1/2012

01-01-2012 | Original Article

Early interim 18F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients

Authors: Pier Luigi Zinzani, Luigi Rigacci, Vittorio Stefoni, Alessandro Broccoli, Benedetta Puccini, Antonio Castagnoli, Luca Vaggelli, Lucia Zanoni, Lisa Argnani, Michele Baccarani, Stefano Fanti

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2012

Login to get access

Abstract

Purpose

The use of early (interim) PET restaging during first-line therapy of Hodgkin’s lymphoma (HL) in clinical practice has considerably increased because of its ability to provide early recognition of treatment failure allowing patients to be transferred to more intensive treatment regimens.

Methods

Between June 1997 and June 2009, 304 patients with newly diagnosed HL (147 early stage and 157 advanced stage) were treated with the ABVD regimen at two Italian institutions. Patients underwent PET staging and restaging at baseline, after two cycles of therapy and at the end of the treatment.

Results

Of the 304 patients, 53 showed a positive interim PET scan and of these only 13 (24.5%) achieved continuous complete remission (CCR), whereas 251 patients showed a negative PET scan and of these 231 (92%) achieved CCR. Comparison between interim PET-positive and interim PET-negative patients indicated a significant association between PET findings and 9-year progression-free survival and 9-year overall survival, with a median follow-up of 31 months. Among the early-stage patients, 19 had a positive interim PET scan and only 4 (21%) achieved CCR; among the 128 patients with a negative interim PET scan, 122 (97.6%) achieved CCR. Among the advanced-stage patients, 34 showed a persistently positive PET scan with only 9 (26.4%) achieving CCR, whereas 123 showed a negative interim PET scan with 109 (88.6%) achieving CCR.

Conclusion

Our results demonstrate the role of an early PET scan as a significant step forward in the management of patients with early-stage or advanced-stage HL.
Literature
1.
Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin’s lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27:1906–14.PubMedCrossRef
2.
Kostakoglu L, Coleman M, Leonard JP, et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med. 2002;43:1018–27.PubMed
3.
Torizuka T, Nakamura F, Kanno T, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging. 2004;31:22–8.PubMedCrossRef
4.
Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52–9.PubMedCrossRef
5.
Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica. 2006;91:475–81.PubMed
6.
Hutchings M, Mikhaeel NG, Fields PA, et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16:1160–8.PubMedCrossRef
7.
Zinzani PL, Tani M, Fanti S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin’s disease patients. Ann Oncol. 2006;17:1296–300.PubMedCrossRef
8.
Querellou S, Valette F, Bodet-Milin C, et al. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin’s lymphoma and Hodgkin’s disease. Ann Hematol. 2006;85:759–67.PubMedCrossRef
9.
Schot BW, Zijlstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood. 2007;109:486–91.PubMedCrossRef
10.
Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-(18F)fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–52.PubMedCrossRef
11.
Gobbi PG, Zinzani PL, Broglia C, et al. Comparison of prognostic models in patients with advanced Hodgkin disease: promising results from integration of the best three systems. Cancer. 2001;91:1467–78.PubMedCrossRef
12.
Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339:1506–14.PubMedCrossRef
13.
Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. 1989;7:630–1636. Erratum in: J Clin Oncol. 1990;8:1602.
14.
Gobbi PG, Broglia C, Di Giulio G, et al. The clinical value of tumor burden at diagnosis in Hodgkin lymphoma. Cancer. 2004;101:1824–34.PubMedCrossRef
15.
Bartlett NL. The present: optimizing therapy – too much or too little? Hematology Am Soc Hematol Educ Program. 2010;2010:108–14.PubMedCrossRef
16.
Dodd LE, Korn EL, Freidlin B, et al. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol. 2008;26:3791–6. Erratum in: J Clin Oncol. 2009;27:2109-2110.PubMedCrossRef
17.
Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 1971;31:1860–1.PubMed
18.
Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244–53. Erratum in: J Clin Oncol. 2000; 18:2351.PubMed
19.
Cheson BD, Pfistner B, Juweid ME, et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.PubMedCrossRef
20.
Kaplan ES, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;58:457–81.CrossRef
21.
Spaepen K, Stroobants S, Dupont P, et al. ((18)F)FDG PET monitoring of tumour response to chemotherapy: does ((18)F)FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging. 2003;30:682–8.PubMedCrossRef
22.
Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2009;37:1824–33.PubMedCrossRef
23.
Gallamini A, Hutchings M, Avigdor A, et al. Early interim PET scan in Hodgkin lymphoma: where do we stand? Leuk Lymphoma. 2008;49:659–62.PubMedCrossRef
24.
Barnes JA, LaCasce AS, Zukotynski K, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin’s lymphoma. Ann Oncol. 2011;22:910–5.PubMedCrossRef
25.
Sher DJ, Mauch PM, Van Den Abbeele A, et al. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin’s lymphoma: the importance of involved-field radiotherapy. Ann Oncol. 2009;20(11):1848–53.PubMedCrossRef
26.
Straus DJ, Johnson JL, Lacasce S, et al. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. 2011;117(20):5314–20.PubMedCrossRef
27.
Strobel K, Schaefer NG, Renner C, et al. Cost-effectiveness therapy remission assessment in lymphoma patients using FDG-PET/CT: is an end of treatment exam necessary in all patients? Ann Oncol. 2007;18:658–64.PubMedCrossRef
28.
Fanti S, Castellucci P, Stefoni V, et al. Early relapse in a patient with Hodgkin’s disease and negative interim FDG-PET. Ann Nucl Med. 2008;22:429–32.PubMedCrossRef
29.
Radford JA, Barrington SF, O’Doherty MJ, et al. Interim results of a UK NCRI randomised trial comparing involved field radiotherapy with no further treatment after 3 cycles ABVD and a negative PET scan in clinical stages IA/IIA Hodgkin lymphoma. Haematologica. 2007;92 suppl 5:S32.
30.
31.
32.
33.
34.
35.
36.
Sánchez-Aguilera A, Montalbán C, de la Cueva P, et al. Spanish Hodgkin Lymphoma Study Group. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood. 2006;108:662–8.PubMedCrossRef
Metadata
Title
Early interim 18F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients
Authors
Pier Luigi Zinzani
Luigi Rigacci
Vittorio Stefoni
Alessandro Broccoli
Benedetta Puccini
Antonio Castagnoli
Luca Vaggelli
Lucia Zanoni
Lisa Argnani
Michele Baccarani
Stefano Fanti
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2012
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-011-1916-8

Other articles of this Issue 1/2012

European Journal of Nuclear Medicine and Molecular Imaging 1/2012 Go to the issue

Editorial Commentary

Standardisation and harmonisation boost the credibility of nuclear medicine procedures

Original Article

Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study

Review Article

Emerging roles for integrated imaging modalities in cardiovascular cell-based therapeutics: a clinical perspective

Original Article

18F-FDG PET/CT for diagnosing infectious complications in patients with severe neutropenia after intensive chemotherapy for haematological malignancy or stem cell transplantation

Original Article

Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma

Original Article

High diagnostic accuracy of low-dose gated-SPECT with solid-state ultrafast detectors: preliminary clinical results